TīmeklisAdditional approved indications in the United States for LAI antipsychotics include bipolar I disorder maintenance treatment for risperidone microspheres and … Tīmeklis2013. gada 15. nov. · Quetiapine. Quetiapine was approved as monotherapy for the treatment of bipolar depressive episodes by the FDA in October 2006. The efficacy of quetiapine in acute bipolar depression is supported by results from 5 studies with quetiapine immediate release (IR) and 1 study with quetiapine extended release (XR).
Understanding Long-Acting Injectable Antipsychotics for …
Tīmeklis2024. gada 14. apr. · This 32-week trial evaluated the safety, pharmacokinetics, and efficacy of multiple-dose administration of Ari 2MRTU 960 in clinically stable adults with schizophrenia or BP-I, versus that of aripiprazole once-monthly 400 mg (AOM 400; an LAI indicated for the maintenance treatment of schizophrenia in adult patients … TīmeklisAvailable data on atypical LAI antipsychotics in BP-I are largely derived from controlled studies of RLAI 44; thus, additional studies on the potential benefits of LAIs in … cup to ml uk conversion
Long-acting injectable antipsychotics (LAIs) for maintenance …
TīmeklisLong-acting injectable (LAI) medication is an attractive alternative to daily dosing of oral medication, especially among patients who are ambivalent about treatment. The … TīmeklisBackground: Non-adherence to medications is a major determinant of poor outcome in bipolar disorder. Second-generation long-acting injectable (LAI) antipsychotics help ensure medication adherence which in turn can lead to more favourable outcomes. Tīmeklis2024. gada 16. sept. · Objective: People with bipolar disorder (BD) often have difficulty with medication adherence. This pilot trial combined a behavioral customized adherence enhancement (CAE) approach with long-acting injectable (LAI) antipsychotic medication and assessed effects on adherence, BD symptoms, and functional status. cup toscana online firenze